Angiotensin-converting enzyme inhibitors improve coronary flow reserve in dilated cardiomyopathy by a bradykinin-mediated, nitric oxide-dependent mechanism

Circulation

Volumn 105, Issue 23, 2002, Pages 2785-2790

  Nikolaidis, Lazaros A ^a   Doverspike, Aaron ^a   Huerbin, Rhonda ^a   Hentosz, Teresa ^a   Shannon, Richard P ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

Angiotensin; Bradykinin; Cardiomyopathy; Microcirculation; Nitric oxide

Indexed keywords

BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; LOSARTAN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONOTROPISM; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; ENDOCARDIUM; EPICARDIUM; HEART DILATATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART PACING; MICROCIRCULATION; NONHUMAN; PRIORITY JOURNAL; STRESS; VASODILATATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BRADYKININ; CARDIOMYOPATHY, DILATED; CORONARY CIRCULATION; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENALAPRILAT; ENZYME INHIBITORS; HEMODYNAMIC PROCESSES; KINETICS; LOSARTAN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROARGININE; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, BRADYKININ B2; RECEPTORS, ANGIOTENSIN; RECEPTORS, BRADYKININ; REGIONAL BLOOD FLOW; VASODILATOR AGENTS;

EID: 0037062701     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000017433.90061.2E     Document Type: Article

References (35)

1. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure: The SOLVD Investigators
2. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions: The SOLVD Investigators
3. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure: SOLVD Investigators
4. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: The SAVE Investigators
5. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomized trial: The Losartan Heart Failure Survival Study ELITE II
6. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study
7. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure
8. 2 kinin receptor gene knockout mice
9. Role of kinins in chronic heart failure and in the therapeutic effect of ACE inhibitors in kininogen-deficient rats
10. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: Role of kinins and angiotensin II type 2 receptors
11. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure
12. 1 angiotensin II receptor inhibition in pacing-induced heart failure: Effects on left ventricular performance and regional blood flow patterns
13. 1 receptor inhibition, and combination therapy with pacing induced heart failure: Effects on left ventricular performance and regional blood flow patterns
14. Reduction of ischemic events with angiotensin-converting enzyme inhibitors: Lessons and controversy emerging from recent clinical trials
15. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions
16. Effects of captopril on ischemic events after myocardial infarction: Results of the Survival and Ventricular Enlargement trial
17. Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy
18. Dynamic limitation of coronary vasodilator reserve in patients with dilated cardiomyopathy and chest pain
19. Differential coronary microvascular function in patients with left ventricular dysfunction of unknown cause: Implication for possible mechanism of myocardial ischemia in early stage of cardiomyopathy
20. Impaired regional subendocardial coronary flow reserve in conscious dogs with pacing-induced heart failure
21. Changes in myocardial blood flow during development of and recovery from tachycardia-induced cardiomyopathy
22. Tachycardia-induced cardiomyopathy: Effects on blood flow and capillary structure
23. Exercise induces cardiac dysfunction in both moderate, compensated and severe hypertrophy
24. Subepicardial segmental function during coronary stenosis and the role of myocardial fiber orientation
25. Direct myocardial and coronary effects of enalaprilat in patients with dilated cardiomyopathy: Assessment by a bilateral intracoronary infusion technique
26. Coronary vasodilation and improved myocardial lactate metabolism after angiotensin converting enzyme inhibition with cilazapril in patients with congestive heart failure
27. Intracoronary enalaprilat improves metabolic coronary vasodilation in patients with idiopathic dilated cardiomyopathy
28. Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure
29. 1receptor blockade on coronary dynamics, function, and structure in postischemic heart failure in rats
30. 1-receptor blockade and angiotensin I-converting enzyme inhibition on coronary flow reserve in postischemic heart failure in rats
31. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat
32. Functional effects of endogenous bradykinin in congestive heart failure
33. Increased bradykinin levels accompany the hemodynamic response to the inhibition of angiotensin-converting enzyme in dogs with heart failure
34. Preserved vasodilator effect of bradykinin in dogs with heart failure
35. Regional myocardial effects of intracoronary bradykinin in conscious dogs